Somer Baburek
CEO
Hera Biotech
10/10Traction
Hera Biotech is commercializing MetriDx™, the first non-surgical diagnostic test for the definitive diagnosis and staging of endometriosis, utilizing micro-fluidic analysis of single cells from uterine brush biopsies. This technology addresses the limitations of current laparoscopic surgical methods, which can miss up to half of endometriosis lesions, by providing accurate and timely diagnoses that can significantly reduce healthcare costs and improve patient outcomes.
- Biotechnology
Updated 22 months ago
Funding
Raised to date
$4.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Althea GroupNo round attributed
- altheagroup.com (opens in a new tab)investor website
HealthinnovationpitchNo round attributed
- healthinnovationpitch.com (opens in a new tab)investor website
KarolinskadevelopmentNo round attributed
- karolinskadevelopment.com (opens in a new tab)investor website
MondayNo round attributed
- monday.capital (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Problem
Current methods for diagnosing endometriosis rely on laparoscopic surgery, an invasive procedure that is expensive and can miss a significant number of lesions. This leads to delays in diagnosis, increased healthcare costs, and prolonged suffering for patients.
Solution
Hera Biotech is developing MetriDx™, a non-surgical diagnostic test for endometriosis that utilizes microfluidic analysis of single cells obtained from uterine brush biopsies. This minimally invasive approach allows for definitive diagnosis and staging of endometriosis, eliminating the need for surgery. MetriDx™ aims to provide clinicians with unprecedented diagnostic capabilities, reduce liability risks within hospitals, and significantly decrease the time it takes for patients to receive an accurate diagnosis. The test analyzes specific biological markers to diagnose endometriosis regardless of the stage, offering a direct pathology diagnosis.
Target Audience
The primary target audience includes OB/GYN practices, fertility clinics, and reproductive endocrinologists seeking a non-surgical method for diagnosing and staging endometriosis.
Features
- Non-surgical diagnosis of endometriosis via uterine brush biopsy, eliminating the need for laparoscopy
- Microfluidic analysis of single cells to identify endometriosis-specific biological markers
- Definitive diagnosis and staging of endometriosis, regardless of the stage of the disease
- Laboratory developed test (LDT) offered to OB/GYN practices and fertility clinics
- Potential to be used as a screening test in OB/GYN and reproductive endocrinologist practices